Introduction
Childhood acute lymphoblastic leukemia (ALL) is a heterogeneous disease in terms of karyotype, immunophenotype and blast morphology. [1] [2] [3] Several genome-wide analyses have described additional genetic changes within individual leukemia clones. [4] [5] [6] Consequently, studies which increase our understanding of the biology and evolution of this disease should provide information on leukemogenic pathways for therapeutic targeting. Such studies may help us understand why initial therapies can induce remission but some cases then relapse, [7] [8] [9] especially as many relapses occur in the low-risk groups.
ALL cells that can generate leukemias in immune deficient mice, termed leukemia initiating cells (LIC), were initially thought to be rare and have a hierarchical structure. [10] [11] [12] [13] Some of these LIC, particularly CD133 + /CD19cells, were resistant to treatment with dexamethasone and vincristine, 13 commonly used in the induction phase of therapy for ALL, so they may survive therapy and eventually cause disease relapse. However, more recent studies using NOD/LtSz-scid IL-2R c null (NSG) mice have revealed that both primitive and more differentiated ALL subpopulations can initiate and maintain acute leukemias in this strain. 5, [14] [15] [16] [17] [18] We and others have shown that CD34 + /CD19 + , CD34 + /CD19and CD34 -B cell precursor (BCP) ALL subpopulations contain LIC. 15, 18 In childhood T-ALL we found that CD34 + /CD7 + , CD34 + /CD7and CD34subpopulations had LIC properties. 18 Another study described CD7 + /CD1aand CD7 + /CD1a + LIC from 1 pediatric and 2 adult T-ALL cases 19 and a study of mature/cortical T-ALL found LIC in both CD34 + /CD7 + and CD34 -/CD7 + populations. 20 The in vivo repopulating capacity has been shown to vary depending on the immunophenotype 18 and genotype of the LIC. 5 These findings demonstrate that LIC are more abundant than earlier studies suggested and indicate that leukemia evolution may have a branching structure rather than a hierarchical one. This has significant implications for therapy of leukemias.
Elimination of the population, which contains the greatest proportion of LIC, or has the greatest self-renewal potential may just lead to another LIC population evolving and expanding to maintain the disease. Consequently, it will be important to develop therapies that can eliminate all populations with LIC potential to prevent further evolution and recurrence. The challenge is to find a way to specifically target LIC without causing toxicity to normal cells. Parthenolide (PTL) has been recently investigated as a potential chemotherapeutic agent for acute myeloid leukemia (AML) and chronic lymphocytic leukemia. [21] [22] [23] [24] [25] [26] PTL is a naturally occurring sesquiterpene lactone used in the treatment of fever, migraines, rheumatoid arthritis and as an anti-inflammatory agent. [27] [28] [29] PTL can induce apoptosis through a range of responses, such as inhibition of nuclear factor molecule kappa B (NF-κB), p53 activation and increase of reactive oxygen species. 21, 23 PTL and DMAPT, an analog of PTL, have been shown to be effective in AML while sparing normal hemopoietic stem cells (HSC). 21, 22 PTL can induce apoptosis in primary B-ALL cells 22 and cell lines. 30, 31 To date there are no reports on the effects of PTL on LIC populations in pediatric ALL. The aim of this study was to evaluate the effects of PTL on childhood ALL cells, especially subpopulations that have LIC activity, including those that have been shown to be resistant to current therapeutic agents. 13 Mean viability of samples on thawing was 83±17% for ALL samples and 71±17% for normal samples.
Methods

Patient cells
Cell sorting
B-ALL cells were stained with antibodies against CD34 (clone 8G12) and CD19
(clone 4G7). T-ALL cells were stained with anti-CD34 and anti-CD7 (clone M-T701).
Normal BM and PB samples were stained with anti-CD34 and anti-CD38 (clone HB7). IgG1 antibodies were used as isotype controls (all BD Biosciences, Oxford, UK). Cells were sorted using a Becton Dickinson Influx Cell sorter (BD Biosciences), using Spigot 6.1.9 software, on the basis of fluorescence intensity after gating on 7aminoactinomycin D (7AAD; Sigma-Aldrich) negative cells with low forward and side scatter. Details of the proportions of nucleated cells in the sorted populations are provided in Supplemental Table 1 . Sorting was performed using the maximum purity setting and the purity of sorted subfractions from each sample was checked during and after sorting. Mice were not preconditioned prior to inoculation. Cells were resuspended in 0.3mL IMDM + 5% HAS and injected into the lateral tail veins of 6-8 week old mice.
Unsorted cells and sorted cell populations were inoculated at a range of doses to obtain estimates of LIC frequency in each subpopulation.
In ex vivo drug sensitivity assays, unsorted cells and sorted subpopulations, from ALL patients and normal donors, were treated with either PTL for 20 to 24 hours or DMSO + phosphate buffered saline (PBS; Invitrogen), as controls, prior to inoculation.
In survival assays, mice were inoculated with bulk ALL cells and sorted subpopulations. Mice were monitored weekly for the presence of human cells in PB aspirates. Once the level of human cells was ≥5%, animals were given daily intravenous doses of PTL (40mg/kg) or placebo (DMSO+PBS) for 9 days. 22, 32 In all assays, animals were monitored weekly for the presence of human cells, maintained for up to 20 weeks and killed electively or until they began to exhibit clinical symptoms of disease. The gross anatomy was inspected and femoral BM samples were removed for flow cytometric and cytogenetic/histologic analyses.
Immunophenotypes of xenografts were examined using antibodies against human CD3, CD10, CD19, CD7, CD33, CD34, CD45 and murine CD45 (all BD Biosciences).
Cytogenetic analysis by FISH was performed by Bristol Genetics Laboratory,
Southmead Hospital, Bristol.
Cells harvested from BM of some engrafted mice were used for serial transplantation experiments. For comparison with primary transplants, equal numbers of human CD45 cells were inoculated into serial recipients. These cells were not enriched for any particular phenotype before evaluation in sequential xenografts.
In vitro drug sensitivity
Unsorted ALL cells and sorted subpopulations were co-cultured with increasing concentrations of PTL (Sigma-Aldrich) for 20 to 24 hours in RPMI-1640 (Sigma-Aldrich) containing 10% FCS and 1% L-glutamine (Invitrogen). Unsorted and (HSC)enriched (CD34 + /CD38 -) NBM samples were also co-cultured with the drug.
Apoptosis and viability were assessed by flow cytometry using annexin V-FITC and propidium iodide (arcus biologicals, Modena, Italy).
Western blotting and confocal microscopy
Cells for Western blotting were prepared by the method described by Foka et al. 33 Full details are provided in the Supplemental data. 
Statistical analysis
Results
LIC frequency in ALL subpopulations
Cells from 15 cases were sorted based on expression of CD34 and CD19 (B-ALL cases, Fig. 1A ) and CD34 and CD7 (T-ALL cases, Fig. 1B ). Cells were inoculated at a range of doses to give an estimate of the frequency of LIC (Table 2) . LIC frequency in sorted subpopulations varied from 1 in 700 to 1 in 9x10 5 but was highest in CD34 + /CD19cells in B-ALL cases and CD34 + /CD7cells in T-ALL cases. As the number of sorted cells available limited the extent of the dilution analysis, these results are likely to be an underestimate of LIC frequencies. Since LIC were readily detectable in all sorted subfractions, we subsequently assessed the effects on PTL on these subpopulations. 
Viability of PTL-treated ALL cells
PTL was initially tested in vitro at a dose range from 0.5-10µM ( Fig. 2A ) in 10 cases.
The IC50 was reached at 7.5µM in 9 cases but 10µM PTL reduced the viability of all cases to ≤43.3%. This higher dose had no effect on the viability of normal HSC (p=0.91, Fig. 2B ). Therefore, 10µM PTL was used routinely thereafter to maximize effects in all patients.
Unsorted cells from 16 of 23 B-ALL cases responded to the drug (<38% viable), 4
showed a partial response (58-71%) and 3 were largely unaffected (>87% viable).
There was a significant reduction in viability in all populations following treatment, Seven of 9 T-ALL cases were affected by PTL (<36% viable) and a partial response was observed in the 2 remaining cases (62-69% viable, Fig. 3D ). Only 27.2±27% 
In vivo engrafting capacity of PTL-treated cells
Unsorted cells and sorted subpopulations from 5 B-ALL cases and 5 T-ALL cases were treated with 10µM PTL for 20-24 hours prior to inoculation to assess whether PTL had any effects on the ability of cells to engraft NSG mice (Fig. 4A ). Groups of 2-4 mice were inoculated with each population assayed. Cell doses which had previously resulted in good engraftment levels were used. The number of sorted cells inoculated varied due to phenotypically primitive cells representing only small proportions of the total leukemia blast population (Supplemental Table 1 ) and different immunophenotypes amongst patients. Treatment of unsorted, CD34 + /CD19 + and CD34 -B-ALL cells with PTL prior to inoculation completely prevented engraftment in every case (Fig. 4B ). PTL treatment of CD34 + /CD19cells significantly reduced or prevented engraftment in 3 cases (pts 17, 22 & 28) . In the other 2 cases, the engrafting capacity of CD34 + /CD19cells from patient 20 was unaffected and engraftment was higher in mice inoculated with PTL-treated cells from patient 6 (98±3%) than with untreated cells (76±12%, Supplemental Fig. 1 ).
FISH analyses on cells recovered from mice engrafted with unsorted and all sorted subpopulations, confirmed these cells had the same karyotype as the patients at diagnosis (91-100% FISH + ). Likewise, cells recovered from animals engrafted with PTL-treated CD34 + /CD19cells from pts 6 and 20 carried the patient specific aberrations (95-100% FISH + ).
Treatment with PTL completely prevented engraftment of unsorted T-ALL cells in 4 of 5 cases (Fig. 4C ). In the remaining case (pt 32) engraftment was significantly reduced to 22±6% compared to untreated cells (77±9%, P<0.001). No engraftment was observed using PTL-treated CD34 + /CD7 + and CD34cells. In 3 cases PTL prevented engraftment of CD34 + /CD7cells and significantly reduced engraftment in 2 cases, from 98±3% to 15±4% (pt 30) and from 52±7% to 16±4% (pt 32), P<0.001. 
Self-renewal capacity of resistant cells
In the 3 cases where in vitro PTL treatment of LIC had little (CD34 + /CD19 -, pts 6, 20) or limited effects (CD34 + /CD7 -, pt 32) on engrafting capacity, cells recovered from murine BM were transplanted into secondary animals to assess the self-renewal ability of the PTL-treated cells (Supplemental Table 4 ). Cells were not re-sorted prior to inoculation into secondary recipients but they received equivalent numbers of human cells as their primary counterparts. Comparable levels of engraftment were observed in the primary and secondary recipients. Inoculated LIC differentiated in vivo to give rise to leukemias that were typical of the patient samples at biopsy.
However, a proportion of the grafts from animals inoculated with PTL-treated or untreated CD34 + /CD19cells remained CD34 + /CD19 -(3.7±0.6%). Likewise, the majority of cells recovered from mice inoculated with treated or untreated CD34 + /CD7cells were CD34 + /CD7 + but 14.2±2.3% remained CD34 + /CD7 -, indicating self-renewal of these primitive LIC.
In vivo activity of PTL in NSG
Unsorted and sorted cell populations from 9 cases were inoculated into NSG and PTL was administered when leukemia was established in the mice (Fig 5A) . Disease progression was prevented in PTL-treated animals, while the leukemia burden in placebo-treated animals continued to rise until they had all succumbed to disease Xenografts of pt 30 had high levels of leukemia prior to treatment (24.2-65.8%).
Following treatment, the levels of human cells detected in treated mice decreased, with the exception of 1 CD34xenograft noted above, and levels of murine hemopoietic cells increased (Supplemental Fig. 3 ). The leukemia burden continued to increase in untreated animals and they all had to be killed between 2-36 days from treatment commencing. All other treated xenografts were disease-free when electively killed up to 18 weeks from commencement of treatment. PTL significantly decreased the leukemia cell burden in all treated animals (P<0.002, Fig. 5D & E) .
With the exception of the 4 xenografts noted above, the majority of cells recovered from PTL-treated animals expressed murine CD45. A representative example of immunophenotypic analyses of BM cells from untreated and PTL-treated xenografts established with CD34 + /CD19cells from pt 20 is shown in Fig. 5F .
Since PTL is a potent inhibitor of NF-κB, we investigated whether this mechanism of action was operational in a cohort of samples, including cases where PTL treatment had limited effects. The effects of the drug on the expression of active and total p65, phospho-IκB and IκB in a representative sample are shown in Supplemental Fig. 4 .
In all cases, there was constitutive expression of active p65 and phospho-IκB. 
Discussion
Outcomes for pediatric leukemias are increasingly successful. Nevertheless, 15-20% of patients relapse due to failure to eradicate the disease and most of these patients will not survive. Most drug efficacy studies focus on initial short-term effects, such as reducing the overall leukemia cell burden. However, if drugs have no effect on the LIC they may expand and eventually cause relapse. In this study we determined the phenotype of LIC a priori in a cohort of childhood ALL cases from mixed prognostic subgroups. LIC were detected in all sorted subpopulations assessed, in agreement with previous reports 15, [18] [19] [20] and were most enriched in the CD34 + /CD19and C34 + /CD7subpopulations in B-and T-ALL cases, respectively. Consequently, we assessed the effects of PTL on unsorted cells and on all subpopulations with LIC activity.
Apoptosis assays indicated that overall PTL reduced the viability of unsorted B-ALL cells to <38% and T-ALL cells to <28%. Patients who were classified as high risk by MRD were less responsive to PTL but an IC50 was reached at 10µM. At this dose PTL had no effect on the viability of CD34 + /CD38 -HSC. These findings are in agreement with Guzman et al, who reported that 53.5% unsorted B-ALL cells survived treatment with PTL. 22 However, the effects of in vitro PTL treatment on CD34 + /CD19 -, CD133 + /CD19 -, CD34 + /CD7and CD34subpopulations were more limited and disappointing compared to the reported effects of PTL and DMAPT in AML. 21, 22 Nevertheless, a limitation of short-term assays is that they only provide a snapshot of the value of a drug at a specific time point. It is crucial to undertake functional studies of drug-treated cells to assess efficacy and targeting of specific cell populations.
When we assessed the capacity of in vitro PTL-treated subpopulations to repopulate NSG mice, engraftment of unsorted and most sorted cell populations was completely prevented or significantly reduced. Interestingly, engraftment of the CD34 + /CD19 -, CD34 + /CD7and CD34subpopulations was severely impaired or completely prevented following PTL treatment, demonstrating that PTL can induce apoptosis in phenotypically primitive and more differentiated LIC and prevent disease establishment in vivo. Since we have previously shown that the functional ability of primitive LIC populations from patients 6, 13, 14, 16, 17 were unaffected by in vitro treatment with dexamethasone and vincristine, 13 the observed reduction in engrafting capacity of multiple LIC subpopulations, following PTL treatment, suggests this drug may be more effective. In vitro treatment of CD34 + /CD19cells from 2 B-ALL cases and CD34 + /CD7cells from 1 T-ALL case had only limited or no detrimental effects on the ability of these cells to engraft NSG mice. These cells could self-renew to repopulate serial NSG and recapitulate the original leukemia phenotype. Our results on the NSG engrafting capacity of in vitro PTL-treated cells are in agreement with results in AML. 21, 22, 25 These findings demonstrate that PTL may have more potential as a therapeutic agent than the results from our short-term apoptosis assays indicated.
To further evaluate therapeutic potential we assessed the activity of PTL in vivo by treating animals with established leukemias. These models more closely mimic the clinical setting and disease progression since the leukemia cells disseminate to extramedullary organs once the BM is engrafted. PTL was well tolerated, with no toxicity observed and resulted in significant reductions in leukemia burden in the BM and extramedullary organs of mice engrafted with unsorted cells and sorted subpopulations. The overall outcome was survival of treated animals with restoration of murine hemopoiesis. Even animals with high leukemia cell burdens (>50% in PB)
prior to treatment were successfully treated and survived until electively killed.
Administration of PTL to xenografts established with CD34 + /CD19cells from pt 20 resulted in elimination of the leukemia and full recovery of murine hemopoiesis. In contrast, in vitro treatment of CD34 + /CD19 -LIC from this patient prior to inoculation into NSG had no effect on the engrafting capacity. These data highlight the importance of conducting drug testing in vivo using xenograft models.
Despite the clear and potent effects of in vivo PTL treatment, specific xenografts from 3 pts (6, 30, 32) were less responsive to the drug. Treatment of these xenografts significantly prolonged survival and reduced leukemia burden but did not prevent progression. Two were high-risk cases, 2 had relapsed at the time of sampling and only 1 is alive at present. PTL was effective in targeting LIC in other high-risk cases and those in relapse, so the lack of response observed in some xenografts cannot be attributed to these factors alone. The survival of all other treated animals and lack of detectable human hemopoiesis, over 120 days after cessation of treatment, is a clear indication of the therapeutic potential of PTL.
Taken together these data indicate that PTL is effective against bulk leukemia and all LIC populations in the majority of cases studied. Had we only assessed the effect of PTL in vivo on unsorted leukemias, disease progression would have been prevented in every case. However, we have shown that 3 specific subpopulations, with both primitive and differentiated phenotypes, from 3 cases were resistant to this drug.
Furthermore, where possible, we demonstrated PTL did not inhibit the NF-κB pathway, one reported mechanism of action, [21] [22] [23] [24] 34 in the resistant LIC in these cases, which may be one reason for the observed lack of effect. Nevertheless, NF-κB was constitutively active in all unsorted samples analyzed. This concurs with a report that 39 of 42 heterogeneous pediatric ALL samples contained activated NF-κB complexes. 35 A comprehensive mechanistic investigation of PTL was beyond the scope of this study. It is possible that the 3 resistant cases had more aggressive disease and that more intensive therapy would be required to ablate specific LIC in these patients.
ALL is currently being treated by a range of drugs, such as glucocorticoids, anthracyclines, vinca alkaloids, asparaginase, alkylating agents and antimetabolites. 36 Despite their different modes and sites of action, most of those agents have been shown to induce NF-κB activation which, ironically, is a selfprotective mechanism for the cell. 37 Using NF-κB inhibitors in combination with chemotherapeutic agents would potentially improve clearance of leukemia cells. The effects of PTL on AML cells can be enhanced when it is used in combination with agents such as with mTOR [38] [39] [40] [41] [42] and PI3K inhibitors. 25 Bortezomib, an inhibitor of the ubiquitin proteasome pathway has been shown to be active in combination with several agents [43] [44] [45] and act synergistically with the mTOR inhibitor RAD001 to kill ALL cells in vitro. 46 Therefore, by combining PTL or DMAPT with mTOR/proteasome inhibitors it may be possible to achieve greater toxicity to pediatric ALL cells. It will be of interest to investigate such drug combinations in the resistant cases from our cohort.
This study represents the first report demonstrating in vivo ablation of multiple LIC populations in childhood ALL. PTL was not dependent on expression of specific cell surface markers and was not restricted to specific subtypes. The findings add to the evidence that some LIC remain resistant to available agents and these cells could subsequently cause relapse. This report also highlights the importance of using animal models of leukemia to conduct drug evaluation studies, rather than just shortterm viability analyses. Results from an untreated and a treated mouse are shown. In histograms, grey peaks represent murine CD45, black peaks are isotype controls. Spleens removed from the treated mouse (left, PTL) and untreated mouse (right, U).
Figure Legends
